A phase 1 first-in-human study of the anti-CD38 dimeric fusion protein TAK-169 for the treatment of patients (pts) with relapsed or refractory multiple myeloma (RRMM) who are proteasome inhibitor (PI)- and immunomodulatory drug (IMiD)-refractory, including pts relapsed/refractory (R/R) or naïve to daratumumab (dara) Meeting Abstract
| Authors: | Kumar, S. K.; Cornell, R. F.; Landgren, O.; Ailawadhi, S.; Higgins, J. P.; Willert, E. K.; Waltzman, R.; Lin, J.; Zhang, Y.; Lublinsky, A. R.; Dash, A. B.; Hanley, M.; Manoharan, D.; Leichter, M.; Ottinger, S.; Labotka, R. J.; Newcomb, J.; Vorog, A. |
| Abstract Title: | A phase 1 first-in-human study of the anti-CD38 dimeric fusion protein TAK-169 for the treatment of patients (pts) with relapsed or refractory multiple myeloma (RRMM) who are proteasome inhibitor (PI)- and immunomodulatory drug (IMiD)-refractory, including pts relapsed/refractory (R/R) or naïve to daratumumab (dara) |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000577160403139 |
| DOI: | 10.1182/blood-2019-125629 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1867 -- Source: Wos |
